GBI MCP Marketplace

Tens of thousands of global drug pipeline records covering every stage of development, from preclinical research and clinical trials to registration applications. Filter by drug, target, indication, emerging technology, development stage, and other key criteria to conduct precise, multidimensional competitive landscape research.

Gathers data from six major clinical trial registration sources: CDE, ClinicalTrials.gov, ChiCTR, China's Human Genetic Resources Administration (HGRAC), Japan's jRCT, and WHO ICTRP. Filter by drug, trial phase, pivotal trials, and other criteria to support clinical development planning and differentiated trial design.

Structured global data on pharmaceutical financing, in-licensing, partnerships, joint ventures, and M&A. Drug, company, and deal-related filters help pharmaceutical companies identify high-potential assets and benchmark valuations precisely.

Tracks drug registration applications in China, including application acceptance details and milestone timelines. Filter by drug, company, registration category, and other criteria to stay on top of submission developments.

Covers marketed drugs across six markets: China, the United States, Japan, the European Union, Canada, and Hong Kong, China. Drug and company filters help businesses map the timing of market entry across major pharmaceutical markets.

Covers China's National Reimbursement Drug List (NRDL), including historical regular listings, nationally negotiated drug lists, and negotiated reimbursement prices. Filter by drug and reimbursement attributes to develop targeted reimbursement access and pricing strategies.

Comprehensive data on provincial and municipal drug tenders, procurement platform listings, and national volume-based procurement awards across China. Detailed insights into winning companies, awarded prices, and contracted volumes support procurement pricing strategies and tender execution.

Covers prescribing information for more than 90% of drugs marketed in China, with full original text. Search by drug, indication, dosage and administration, boxed warnings, contraindications, adverse reactions, and drug interactions to support medical content development and drug evaluation with standardized, reliable information.

Consolidates lists of drugs using innovative access channels, including Huiminbao supplementary health insurance and patient assistance programs (PAPs), providing comprehensive intelligence on commercialization and access opportunities for innovative drugs in self-pay and diversified payer markets.

Covers more than 5 million researchers across China, bringing together extensive public-domain data on master data, scientific publications, clinical trials, grants, guidelines, professional societies, conferences, and collaborations to deliver comprehensive, in-depth HCP profiles.

Tracks HCP publications over time using public sources including PubMed, CNKI, and Wanfang, helping assess experts’ scientific output, research focus, and research activity.

Tracks global clinical trials led by or involving HCPs over time, identifying their roles as principal investigators (PIs) or site investigators to help companies evaluate and identify clinical experts for new drug trials.

Tracks HCP contributions to authoritative domestic and international clinical guidelines and expert consensus statements. Links HCPs to evidence of academic authority to identify leading KOLs who shape standards of care.

Tracks research grants led by HCPs, connecting projects from sources including the National Natural Science Foundation of China, China's National Key R&D Program, and the US National Institutes of Health to support early planning for translational research and industry–academia collaboration.

Tracks HCP activities as conference chairs, session moderators, panelists, and invited speakers. Consolidated records from major medical conferences in China and worldwide provide up-to-date visibility into experts’ conference participation.

Tracks HCP appointments in professional societies, with structured organizational data on societies and specialist committees at all levels, including the Chinese Medical Association and the Chinese Society of Clinical Oncology (CSCO), to assess experts’ professional influence and academic standing.

Tracks HCP collaborations with domestic and international pharmaceutical companies across clinical trials, publications, conferences, and other activities, revealing collaboration preferences and the strength of relationships with competitors.

Tracks academic collaboration among HCPs through co-authored publications, joint clinical trials, conferences, and other activities to uncover their professional networks.

Covers abstracts across PubMed and publicly available full texts. Retrieve relevant literature through natural-language questions to significantly shorten literature research cycles.

Covers public materials from leading global clinical congresses, including ASCO, ESMO, ASH, ADA, and AACR. Vector-based semantic matching retrieves oral presentation, poster, and late-breaking abstract (LBA) content to track emerging scientific developments and opportunities for competitive differentiation.

Covers major pharmaceutical news and policy and regulatory documents from China and worldwide. Vector-based semantic search and entity-linked retrieval help companies quickly understand industry developments.